Evidence map›Paper›PMID 27604375›Full record

ReviewWorld journal of urology2017

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).

Francesco Soria, Shahrokh F Shariat, Seth P Lerner, Hans-Martin Fritsche, Michael Rink, Wassim Kassouf, Philippe E Spiess, Yair Lotan, Dingwei Ye, Mario I Fernández and 5 more

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07077447 (DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma), which is not on this map. Cited by 253 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
253citing papers in PubMed, 12 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07077447 recruitingnot on this mapstarted 2025, after this paper: background citation

DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma

TypeobservationalSponsorZealand University HospitalRan2025 to 2040Enrolled2,500ConditionsUpper Urinary Tract Urothelial CarcinomaArmsKidney sparing surgery for high-risk upper urinary tract urothelial carcinoma
3 · Its place in the literature

Who cites it

253 citing papers in PubMed, 12 syntheses or guidelines pooled it, 460 citations in OpenAlex.

  1. SEOM-SOGUG clinical guideline for urothelial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article

193 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 15 institutions in 10 countries.

Francesco SoriaDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Seth P LernerScott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Hans-Martin FritscheDepartment of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
Michael RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Wassim KassoufDepartment of Surgery (Urology), McGill University, Montreal, QC, Canada.
Philippe E SpiessDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Yair LotanDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mario I FernándezDepartment of Urology, Clinica Alemana, Santiago, Chile.
Eiji KikuchiDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Daher C ChadeUrology Department, University of Sao Paulo Medical School and Institute of Cancer, São Paulo, Brazil.
Marko BabjukDepartment of Urology, Faculty Hospital Motol, Second Faculty of Medicine, Charles University in Praha, Prague, Czech Republic.
Arthur P GrollmanDepartment of Pharmacological Sciences and Department of Medicine, Stony Brook University, Stony Brook, NY, USA.
George N ThalmannDepartment of Urology, Bern University Hospital, Bern, Switzerland. george.thalmann@insel.ch.
Baylor College of Medicine · USCharles University · CZClínica Alemana · CLFudan University Shanghai Cancer Center · CNInstituto do Câncer do Estado de São Paulo · BRKarl Landsteiner Society · ATKeio University · JPMcGill University · CAMedical University of Vienna · ATMoffitt Cancer Center · USStony Brook University · USThe University of Texas Southwestern Medical Center · USUniversity Hospital of Bern · CHUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUpper-tract urothelial carcinoma (UTUC) is a relatively uncommon disease with limited available evidence on specific topics. The purpose of this article was to review the previous literature to summarize the current knowledge about UTUC epidemiology, diagnosis, preoperative evaluation and prognostic assessment.

methodsUsing MEDLINE, a non-systematic review was performed including articles between January 2000 and February 2016. English language original articles, reviews and editorials were selected based on their clinical relevance.

resultsUTUC accounts for 5-10 % of all urothelial cancers, with an increasing incidence. UTUC and bladder cancer share some common risk factors, even if they are two different entities regarding practical, biological and clinical characteristics. Aristolochic acid plays an important role in UTUC pathogenesis in certain regions. It is further estimated that approximately 10 % of UTUC are part of the hereditary non-polyposis colorectal cancer spectrum disease. UTUC diagnosis remains mainly based on imaging and endoscopy, but development of new technologies is rapidly changing the diagnosis algorithm. To help the decision-making process regarding surgical treatment, extent of lymphadenectomy and selection of neoadjuvant systemic therapies, predictive tools based on preoperative patient and tumor characteristics have been developed.

conclusionsAwareness regarding epidemiology, diagnosis, preoperative evaluation and prognostic assessment changes is essential to correctly diagnose and manage UTUC patients, thereby potentially improving their outcomes.

Indexed as

Aristolochic AcidsCarcinoma, Transitional CellColorectal Neoplasms, Hereditary NonpolyposisHumansKidney NeoplasmsKidney PelvisLymph Node ExcisionNeoadjuvant TherapyPreoperative CarePrognosisRisk FactorsUreteral NeoplasmsUreteroscopyUrinary Bladder Neoplasmsaristolochic acid IAristolochic AcidsDiagnosisEpidemiologyNew technologiesPredictive toolsPrognosisRisk factorUTUC

Identifiers

PMID27604375
OpenAlexW2509447503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.